[Primary XXXX : an infrequent cause of focal @entity99 ].

@entity1 @entity1667 @entity1893 @entity1326 @entity2617 @entity75 @entity2225 @entity1195 @entity786 @entity1892 @entity1778 @entity2719 @entity6687 @entity99
Primary @entity99 (PHL) is confined to the liver with no evidence of @entity6687 . Histopathologically, the PHL belongs to the group of @entity1893 and the most common subtype is the diffise large @entity1892 . We present a 72-year-old @entity1 , with no relevant antecedents and the following symptoms: early satiety, abdominal discomfort and rapid weight loss. Liver function tests are normal, erythrocyte sedimentation rate is accelerated and LDH progressively increases during the hospitalization. Imaging studies (ultrasound, CT scan, nuclear magnetic resonance) show a multilobued mass of around 12 cm of diameter in the right hepatic lobe. Tumoral and virological markers are negative. The pathology of an echo-guided biopsy informs a massive infiltration by a diffuse large @entity1892 . The immunohistochemical study shows @entity2225 +, @entity1195 + and negative CD3, CKAE1, @entity1326 , Hepatocyte and HMB45. The citology of pleural liquid is negative for atypia, peripheral blood smear shows no signs of @entity1778 , bone marrow biopsy is negative for @entity2617 , and @entity2719 scintigraphy and body CT scan do not reveal @entity75 . The @entity1 starts chemotherapy with @entity786 and @entity1667 but worsens and dies two weeks after beginning treatment. We conclude that our @entity1 had a rare disease with an unresectable lesion, poor prognostic factors and high recurrence risk. Chemotherapy is the treatment of choice in these cases.
